0001396814-24-000037.txt : 20240308
0001396814-24-000037.hdr.sgml : 20240308
20240308173351
ACCESSION NUMBER: 0001396814-24-000037
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240306
FILED AS OF DATE: 20240308
DATE AS OF CHANGE: 20240308
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PACE GARY W
CENTRAL INDEX KEY: 0001184778
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35060
FILM NUMBER: 24735764
MAIL ADDRESS:
STREET 1: C/O RESMED INC
STREET 2: 14040 DANIELSON STREET
CITY: POWAY
STATE: CA
ZIP: 92064-6857
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pacira BioSciences, Inc.
CENTRAL INDEX KEY: 0001396814
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 510619477
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5401 WEST KENNEDY BOULEVARD
STREET 2: SUITE 890
CITY: TAMPA
STATE: FL
ZIP: 33609
BUSINESS PHONE: 813-553-6680
MAIL ADDRESS:
STREET 1: 5401 WEST KENNEDY BOULEVARD
STREET 2: SUITE 890
CITY: TAMPA
STATE: FL
ZIP: 33609
FORMER COMPANY:
FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20101029
FORMER COMPANY:
FORMER CONFORMED NAME: PACIRA INC
DATE OF NAME CHANGE: 20080318
FORMER COMPANY:
FORMER CONFORMED NAME: Blue Acquisition Corp
DATE OF NAME CHANGE: 20070418
4
1
wk-form4_1709937219.xml
FORM 4
X0508
4
2024-03-06
0
0001396814
Pacira BioSciences, Inc.
PCRX
0001184778
PACE GARY W
C/O PACIRA BIOSCIENCES, INC.
5401 WEST KENNEDY BOULEVARD, SUITE 890
TAMPA
FL
33609
1
0
0
0
0
Common Stock
2024-03-06
4
S
0
1066
29.67
D
140384
D
Common Stock
2024-03-07
4
S
0
28257
30.81
D
112127
D
Common Stock
2024-03-08
4
S
0
90000
30.60
D
22127
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.550 to $30.965, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 1 and 2.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.300 to $30.860, inclusive.
/s/ Kristen Williams, Attorney-in-Fact
2024-03-08